Hyperion raises $40 million in venture funds 

South San Francisco’s Hyperion Therapeutics, a biopharmaceutical firm specializing in gastrointestinal and hepatology therapies, has raised $40 million in a second round of venture funding.

Sofinnova Ventures was the lead investor, with equal commitments from Highland Capital Partners and NEA, all of them based in Menlo Park.

WRF Capital of Seattle, Wash. also invested.

About The Author

Staff Report

Staff Report

Bio:
A daily newspaper covering San Francisco, San Mateo County and serving Alameda, Marin and Santa Clara counties.
Pin It
Favorite

Speaking of Business

More by Staff Report

Latest in Business & Real Estate

Monday, Jul 16, 2018

Videos

© 2018 The San Francisco Examiner

Website powered by Foundation